|
|
|
|
|
|
DISCOVER THE SCIENTIFIC PROGRAMME |
|
|
|
|
OPEN TO THE PUBLIC CONFERENCE “DIALOGUE ON BRONCHIECTASIS” |
|
|
We are delighted to invite you to the Open to the Public Conference: “Dialogue on Bronchiectasis” |
📅 Saturday, February 22nd ⌚ 16:00 – 18:30 📍 Sorbonne University International Conference Center (CICSU) or virtually 🌍 Language: French and English with simultaneous translation |
This open to the public conference aims to raise awareness about the impact of bronchiectasis on patients, families and caregivers, while highlighting the French healthcare system's solutions for improved management. |
|
|
|
|
|
|
ASSOCIATION & PATIENT PROGRAMME |
|
|
|
|
We are proud to host the Association & Patient Programme in collaboration with European Lung Foundation The Patient Programme aims to promote greater awareness and understanding of Bronchiectasis, through bringing diverse voices and perspectives together in the fight against this disease. 📣 Share this important news with your patients and encourage them to participate! 🎟 Free registration – available for both onsite and virtual attendance. |
| 👉 Find out more and register now |
|
|
TWO OF OUR HEADLINE TALKS |
|
|
We’re very proud to present this year’s Scientific Programme, now officially accredited |
|
|
|
|
Here are just some of the brilliant headline talks you can expect to see:
Prof. Bush Imperial College and Royal Brompton Hospital Bronchiectasis reversal in children - is it possible?
The traditional definition of bronchiectasis is that it is irreversible; however, in children and even in adults, airway dilatation may sometimes reverse.
Although unproven, it is likely that early, aggressive treatment of airway dilatation is more effective when initiated in the early stages.
Regardless of whether airway dilatation is present, chronic airway neutrophilic inflammation and infection should be treated aggressively to minimize the risk of disease progression.
Prof. Shteinberg Carmel Medical Center and the Technion, Haifa Eosinophilic inflammation in bronchiectasis: more than just blood eosinophil count
As the aetiologies of bronchiectasis are variable, the inflammation in bronchiectatic airways is also variable.
About 20% of patients with bronchiectasis have eosinophilic inflammation.
Blood eosinophil count is an imperfect marker, so alternative ways of identifying individuals with eosinophilic inflammation are needed.
Therapies targeted at eosinophilic inflammation may benefit this subset of patients.
For more information about all of the great talks at EBROW: Scientific Programme |
|
|
LATE-BREAKING ABSTRACT SUBMISSION |
|
|
Our dedicated Poster Sessions give you the opportunity to share your work:
Additionally, you’ll get invaluable feedback from the faculty, including guidance around advancing your career towards becoming conference faculty yourself. Late-Breaking Abstract Window – 24th January – 3rd February 2025 |
| quick submission guidelines |
|
|
|
|
We would like to extend our gratitude to our media partners. |
 |
 |
 |
|
|
|
|
We are also on social media and we will be sharing #EBROW25 information on |
|
|
|
|
ORGANISING SECRETARIAT
Address: 74 Boulevard d’Italie, 98000 MONACO Phone number: +377 97 97 35 55 |
E-mail: info@bronchiectasis-eu.org |
|
|
|
|